New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 30, 2012
18:11 EDTYHOO, CBE, HF, S, SCMP, ETN, NTLSOn The Fly: After Hours Movers
HIGHER: NTELOS (NTLS), up 25% after falling 20% during the trading day on concerns over agreement with Sprint (S)... Cooper Industries (CBE), up 6% after transaction to be acquired by Eaton (ETN) is completed... HFF (HF), up 3% after declaring special dividend... LOWER: Yahoo! (YHOO), down 1% after a Mexican judge ordered the company to pay $2.7B in a non-final judgment... Sucampo Pharmaceuticals (SCMP), down 8% after FDA extends drug review to April.
News For NTLS;S;CBE;ETN;HF;YHOO;SCMP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 >>
September 2, 2015
16:15 EDTYHOOYahoo completes Polyvore acquisition
Subscribe for More Information
10:20 EDTYHOOYahoo calls active
Subscribe for More Information
10:10 EDTYHOORumor: Yahoo active on renewed takeover chatter
Subscribe for More Information
September 1, 2015
13:34 EDTSSprint to invest nearly $150M in Chicago by end of 2016
Subscribe for More Information
10:49 EDTYHOOYahoo CEO Marissa Mayer announces pregnancy, plans limited time off
Subscribe for More Information
August 31, 2015
12:04 EDTYHOOStocks with call strike movement; BABA YHOO
Subscribe for More Information
August 28, 2015
05:59 EDTSSprint offers DirecTV customers free year of cell service
Subscribe for More Information
August 27, 2015
20:05 EDTSSprint offers DirecTV customers free year of cell service, WSJ says
Subscribe for More Information
11:25 EDTSSamsung Pay beta available on all U.S. carriers except Verizon, Verge reports
Samsung (SSNLF) Pay's beta is available on all major U.S. carriers, including AT&T (T), Sprint (S), T-Mobile (TMUS), and U.S. Cellular (USM), except for Verizon (VZ), the Verge reports. Verizon is "evaluating" Samsung Pay currently, and may very well miss the September 28th launch of the product, the report says. Reference Link
09:12 EDTSCMPSucampo price target raised to $36 from $31 at H.C. Wainwright
H.C. Wainwright said Sucampo's proposed acquisition of its supplier R-Tech Ueno is about "a lot more" than just lower costs and direct control over the supply chain, noting that Sucampo will also acquire several early pipeline assets via the deal. The firm, which contends that the market has "yet to fully comprehend the impact of this acquisition," raised its price target on Sucampo shares to $36 from $31.
06:33 EDTYHOOYahoo announces Tumblr sharing tools at Mobile Developer Conference
Subscribe for More Information
August 26, 2015
10:00 EDTETNOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
09:33 EDTSActive equity options trading on open
Subscribe for More Information
09:03 EDTETNEaton upgraded to Buy from Hold at Vertical Research
07:47 EDTSCMPSucampo to host conference call
Subscribe for More Information
06:19 EDTSCMPSucampo launches tender offer to acquire R-Tech Ueno for $278M
Sucampo Pharmaceuticals announced the launch of an all-cash tender offer in Japan by Sucampo's Japanese subsidiary and the execution of a separate share purchase agreement with certain shareholders of R-Tech Ueno to acquire all outstanding shares of R-Tech Ueno for a total consideration of JPY33 billion, or approximately $278M, inclusive of approximately $54M in cash and 2.5M Sucampo shares, held by R-Tech Ueno. The purchase price reflects a 16% premium over R-Tech Ueno's one-month volume weighted average price and a 16% premium over R-Tech Ueno's three-month volume weighted average price. Assuming a successful completion of the acquisition, for full year 2016, excluding amortization and debt costs related to the proposed transaction, Sucampo expects to achieve net income of $55M to $60M , earnings per share of $1.20 to $1.30, and adjusted EBITDA of $95M to $100M. In addition, Sucampo expects to achieve pre-tax operational synergies of approximately $5M on an annualized basis in 2016. Sucampo does not expect the acquisition to have a material impact on 2015 results given the expected timing of transaction close. R-Tech Ueno is a Japanese pharmaceutical company that manufactures AMITIZA for Sucampo and Sucampo's commercialization partners, Takeda Pharmaceuticals, Mylan N.V. and Harbin Gloria Pharmaceuticals. R-Tech Ueno also receives revenue from sales of RESCULA in Japan. In addition, the company has a diverse pipeline of drug candidates in various stages of development in gastroenterology, ophthalmology, autoimmune and inflammatory diseases, and oncology. In the tender offer, which has been unanimously approved by the Board of Directors of both companies, Sucampo's Japanese subsidiary Sucampo Pharma, LLC will offer JPY1,900 per share in cash for the shares of R-Tech Ueno. Sucampo is expecting to acquire 56% of the outstanding shares of R-Tech Ueno in the tender offer. Separately, Sucampo has entered into agreement with R-Tech Ueno's founders and a related entity to acquire the remaining 44% of R-Tech Ueno shares for JPY1,400 per share; the closing of this share purchase is conditioned on the closing of the tender offer. The tender offer period is expected to end on October 13, 2015, assuming the tender offer achieves the minimum acceptance threshold, regulatory approvals and other customary conditions, subject to our right to extend the offer. Following completion of the tender offer and the closing of the share purchase agreement with the founders, Sucampo will acquire all remaining outstanding shares of R-Tech Ueno not acquired through the tender offer through a squeeze-out process. The squeeze out process may take up to 13 weeks to complete. The aggregate acquisition price of R-Tech Ueno will be approximately $278 million. Sucampo expects to close the acquisition in the fourth quarter of 2015.
August 25, 2015
06:13 EDTYHOOThird Point, FTC settle over antitrust filings for 2011 Yahoo stake
Three affiliated hedge fund companies and their management company, Third Point LLC, have agreed to settle Federal Trade Commission charges that they violated premerger reporting laws in connection with their 2011 acquisitions of stock in Yahoo! Inc. The complaint alleges that Third Point Partners Qualified L.P., Third Point Ultra, LTD, and Third Point Offshore Fund, LTD failed to observe the filing and waiting requirements of the Hart-Scott-Rodino Act before purchasing shares in Yahoo. According to the complaint, the three defendant funds claimed that they were exempt from reporting to the U.S. antitrust authorities because the purchases were made solely for investment purposes. At the time of the stock purchases, however, defendant Third Point LLC, which made investment decisions on behalf of the funds, was taking actions inconsistent with an investment-only intent, such as communicating with third parties to determine their interest in becoming the CEO or a board candidate of Yahoo. Under the terms of the proposed stipulated five-year federal court order, the defendants are prohibited from relying on the investment-only exemption if they have contacted third parties to gauge their interest in joining the board of the target company, communicated with the target company about proposed candidates for its board, or engaged in other specified conduct in the four months prior to acquiring voting securities above the HSR Act threshold. In this case, the agencies determined not to seek civil penalties based on several factors, including that the violation was inadvertent and short-lived, and this was the defendants' first violation of the HSR Act.
06:06 EDTSStocks with implied volatility below IV index mean; S GOOG
Stocks with implied volatility below IV index mean; Sprint (S) 77, Google (GOOG) 41 according to iVolatility.
August 24, 2015
09:45 EDTSCMPOn The Fly: Analyst Initiation Summary
Subscribe for More Information
07:29 EDTSCMPSucampo initiated with a Buy at H.C. Wainwright
Subscribe for More Information
1 | 2 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use